These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38927535)

  • 1. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.
    Srkalovic G; Nijim S; Srkalovic MB; Fajgenbaum D
    Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers and Signaling Pathways Implicated in the Pathogenesis of Idiopathic Multicentric Castleman Disease/Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, Renal Insufficiency, and Organomegaly (TAFRO) Syndrome.
    Sumiyoshi R; Koga T; Kawakami A
    Biomedicines; 2024 May; 12(6):. PubMed ID: 38927348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
    Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
    Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
    Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
    Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?
    Takai K
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
    Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
    Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
    Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
    Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
    Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
    Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International definition of iMCD-TAFRO: future perspectives.
    Nishimura Y; Nishimura MF; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
    Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
    J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic basis for iMCD-TAFRO.
    Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
    Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
    Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
    Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
    Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
    Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report.
    Shiina T; Yamamoto EK; Yamada H; Sendo S; Kanzawa M; Saegusa J
    Mod Rheumatol Case Rep; 2024 Aug; ():. PubMed ID: 39177383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAFRO Syndrome.
    Igawa T; Sato Y
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
    Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
    Front Immunol; 2019; 10():1489. PubMed ID: 31316523
    [No Abstract]   [Full Text] [Related]  

  • 20. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
    Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K
    BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.